drugset / Trial / NCT01188707
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Phase 1/2
Terminated
5 enrolled
Herlev Hospital
Bispebjerg Hospital · collabCopenhagen University Hospital at Herlev · collabRoche Pharma AG · collabValerio Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
The Belinostat-Erlotinib trial is designed as an open, non randomized phase I / II trial to assess the efficacy and safety of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer who are eligible for treatment with erlotinib.
Timeline
- Start
- 2010-10-01
- Primary completion
- 2011-06-30
- Completion
- 2011-06-30
Outcome
Outcome not reported
Stopped: “Dose over MTD reached”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 500 mg | — |
| Subject | Belinostat | Small molecule | 750 mg | — |
| Subject | Belinostat | Small molecule | 1000 mg | — |
| Subject | Belinostat | Small molecule | 1250 mg | — |
| Subject | Belinostat | Small molecule | 1500 mg | — |
| Subject | Erlotinib | Small molecule | 150 mg | — |